Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry , J Immunother Cancer, 13(2): 2025,e009890

Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ. Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease , Clin Lymphoma Myeloma Leuk, 25(1): 2025,45-51

Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy , Transplant Cell Ther, 00912-1.(25): 2025,S2666-6367

Landsburg, DJ Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing , Cancers (Basel), 17(1): 2024,18

Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF. Genomic features of newly diagnosed large B cell lymphoma with or without subsequent disease progression , Cancer Res Commun, 4(11): 2024,2947-2954

Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ. Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP , Haematologica, 110: 2024,doi: 10.3324/haematol.2024.286560.

Schneider, Michael, Landsburg, Daniel The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review , Annals of Lymphoma, 8: 2024,doi: 10.21037/aol-23-19

Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A. TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era , Blood Adv, 7(23): 2023,7243-7253

Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL. Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells , Transplant Cell Ther, 29(8): 2023,495-503.

Landsburg DJ, Morrissette JJD, Schuster SJ, Nasta SD, Gerson JN, Barta SK, Svoboda J, Chong EA, Lim MS. Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas , Oncotarget, 13: 2022,1237-1244